Compare Manulife Financial Corporation (MFC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Merck & Co., Inc. — how do they compare? Manulife Financial Corporation trades at $42.43 (market cap $69.48B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 5.1× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and Merck & Co., Inc. for 98 Days on average.
| MFC | MRK | |
|---|---|---|
Market Cap | $69.48B | $351.28B |
Volume | 1,347,508 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $44.77 | $156.43 |
52-Week Low | $31.64 | $82.49 |
Typical Hold Time | 119 Days | 98 Days |
Enterprise Value | $64.75B | $398.04B |
Dividend Yield | 3.23% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.12, up 1.08% today, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 earnings of $0.79 per share, beating expectations, and revenue growth is projected to reach $57.5 billion in 2026. Recent news includes a new $750 million subordinated notes offering and executive appointments, while institutional investors like Bank of America have increased positions.
The outlook is mixed with strong fundamentals and analyst buy ratings but bearish technicals and a consensus price target below the current price. Key risks include competitive pressures and market volatility, while opportunities lie in continued earnings growth and Asia market expansion.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
